A strong indication of the possible involvement of DJ-1 in ALS comes from the recent approval in the US and Canada of a new drug for the treatment of ALS, composed of a fixed-dose combination of taurursodiol and sodium phenylbutyrate. Here, PARK7 is linked to amyotrophic lateral sclerosis.